Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $151,362.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 2,803 shares of the company's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $54.00, for a total value of $151,362.00. Following the completion of the sale, the insider now owns 92,231 shares of the company's stock, valued at $4,980,474. This represents a 2.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Thursday, May 15th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $39.30, for a total transaction of $393,000.00.
• On Tuesday, April 15th, Catriona Yale sold 9,073 shares of Akero Therapeutics stock. The shares were sold at an average price of $37.91, for a total value of $343,957.43.
• On Monday, March 17th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $44.76, for a total value of $447,600.00.

Akero Therapeutics Stock Up 2.9%

NASDAQ:AKRO traded up $1.55 on Friday, hitting $55.11. 1,356,860 shares of the company's stock were exchanged, compared to its average volume of 1,476,598. The firm has a 50-day moving average price of $43.53 and a 200-day moving average price of $40.13. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 52 week low of $21.02 and a 52 week high of $58.40. The company has a market cap of $4.39 billion, a P/E ratio of -14.70 and a beta of -0.16.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $1.91. As a group, analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Akero Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. RTW Investments LP lifted its stake in Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock valued at $190,840,000 after acquiring an additional 940,388 shares during the last quarter. Deep Track Capital LP grew its holdings in Akero Therapeutics by 116.0% during the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company's stock worth $41,452,000 after purchasing an additional 800,216 shares during the period. Balyasny Asset Management L.P. acquired a new position in Akero Therapeutics during the fourth quarter worth approximately $18,059,000. SG Americas Securities LLC raised its stake in Akero Therapeutics by 93.3% in the first quarter. SG Americas Securities LLC now owns 1,155,787 shares of the company's stock valued at $46,786,000 after buying an additional 557,794 shares during the period. Finally, Lord Abbett & CO. LLC bought a new stake in Akero Therapeutics in the first quarter valued at approximately $21,333,000.

Wall Street Analyst Weigh In

Several analysts have commented on AKRO shares. Bank of America raised their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. HC Wainwright raised their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a report on Monday, March 3rd. Citigroup reduced their target price on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Finally, Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Akero Therapeutics has a consensus rating of "Buy" and a consensus price target of $82.50.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.